Differential effects of treatment targets on risks of adverse outcomes according to diabetes duration, age and complications: Can these characteristics be used to individualize diabetes treatment? The Rio de Janeiro type 2 diabetes cohort

• Published in: Journal of diabetes and its complications 2022-02, Vol.36 (2), p.108124-108124, Article 108124
• Main Authors: Cardoso, Claudia R.L., Leite, Nathalie C., Salles, Gil F.
• Format: Article
• Language: English
• Subjects: Age; Aged; Ankle; Antihypertensives; Blood pressure; Brazil - epidemiology; Cardiovascular disease; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Cardiovascular events; Cholesterol; Cohort analysis; Cohort study; Creatinine; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Heart failure; Humans; Hypertension; Hypoglycemia; Laboratories; Life expectancy; Low density lipoprotein; Microvascular complications; Mortality; Peripheral neuropathy; Prognosis; Prospective Studies; Risk Factors; Treatment targets; Type 2 diabetes
• ISSN: 1056-8727; 1873-460X
• DOI: 10.1016/j.jdiacomp.2021.108124

To investigate interactions between more/less strict treatment targets (HbA1c, systolic blood pressure, LDL-cholesterol) and clinical characteristics (age, diabetes duration and presence of complications) for occurrence of cardiovascular/microvascular complications and mortality in type 2diabetes. 690 individuals were followed-up for 10 years (median). Interactions between treatment targets, estimated as mean values during the first 2-years, and clinical characteristics were tested in multivariable Cox regressions adjusted for other risk factors. Hazard ratios (HRs) were estimated in stratified analyses for cardiovascular/microvascular outcomes and mortality. During follow-up, 214 patients had a cardiovascular event (175 MACEs); and 265 died (132 cardiovascular deaths); there were 206 renal, 161 retinopathy and 181 peripheral neuropathy events. There were interactions between treatment parameters and clinical characteristics, in most of them the HRs were higher in older individuals, in those with longer diabetes durations and with complications, particularly for the cardiovascular outcomes and mortality. For microvascular outcomes the opposite was observed. For cardiovascular mortality, the HRs of higher HbA1c were 1.31 (1.08–1.58) and 1.09 (0.88–1.34), respectively with longer/shorter diabetes duration (p-for-interaction 0.11); and 1.43 (1.14–1.79) and 1.02 (0.85–1.23) in older/younger individuals (p-for-interaction 0.019). Our findings do not support less strict treatment targets for older individuals, with longer diabetes duration or with complications, particularly for cardiovascular and mortality prevention. •Treatment targets of diabetes shall be individualized based on age, diabetes duration and presence of complications.•The risks associated with poorer metanolic and BP control were equivalent or higher than in younger individuals.•As well they were equivalent or higher in those with longer than shorter diabetes duration, and in those with complications.•This disparity was more marked for mortality and for adverse cardiovascular outcomes than for microvascular outcomes.•These findings do not support less strict treatment targets according to these clinical characteristics.